JPMorgan Chase & Co. Has $7.91 Million Stake in Integra LifeSciences Holdings Corporation $IART

JPMorgan Chase & Co. reduced its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 92.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 551,732 shares of the life sciences company’s stock after selling 7,249,229 shares during the period. JPMorgan Chase & Co.’s holdings in Integra LifeSciences were worth $7,906,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after acquiring an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Integra LifeSciences in the 1st quarter valued at $277,000. Goldman Sachs Group Inc. boosted its position in shares of Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Integra LifeSciences by 21.3% during the second quarter. Legal & General Group Plc now owns 261,242 shares of the life sciences company’s stock worth $3,205,000 after purchasing an additional 45,825 shares during the period. 84.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IART has been the topic of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday. Wells Fargo & Company upgraded Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Citigroup cut their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $14.40.

Integra LifeSciences Stock Performance

Shares of IART opened at $9.12 on Tuesday. The firm has a market cap of $710.81 million, a P/E ratio of -1.36 and a beta of 1.02. Integra LifeSciences Holdings Corporation has a twelve month low of $8.70 and a twelve month high of $22.27. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The firm’s 50 day moving average price is $10.60 and its two-hundred day moving average price is $12.39.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same quarter in the prior year, the firm earned $0.97 earnings per share. The firm’s revenue was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.